Sandoz Group (OTCMKTS:SDZNY) Shares Up 3.3% – What’s Next?

Shares of Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) traded up 3.3% during mid-day trading on Friday . The company traded as high as $76.84 and last traded at $76.84. 2,413 shares were traded during mid-day trading, a decline of 92% from the average session volume of 29,782 shares. The stock had previously closed at $74.40.

Wall Street Analyst Weigh In

Separately, Barclays upgraded Sandoz Group to a “strong-buy” rating in a research note on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Sandoz Group currently has a consensus rating of “Moderate Buy”.

Sandoz Group Stock Performance

The firm has a 50-day simple moving average of $68.75 and a two-hundred day simple moving average of $61.80. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.82 and a current ratio of 1.29.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.